All clinical staff members are welcome to participate. Only 2016 diamond and platinum corporate members may participate. Please let Mary Jo Richards know if you want to participate at Maryjo@mjexecmgmt.com. Click Here for more information.
The U.S. Food and Drug Administration today approved Tecentriq (atezolizumab) to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.